Spectrum Journal of Innovation, Reforms and Development
Volume 15, May, 2023 | ISSN (E): 2751-1731
Website: www.sjird.journalspark.org

THE EFFECTIVENESS AND FUTURE DIRECTIONS OF CPR SIMULATORS IN HEALTHCARE TRAINING

Parpibaeva D.A.,
Ergashov N.Sh.,
Salaeva M.S.,
Salimova N.D.,
Boltaboev X.Q.,
Turbanova U.V.
Tashkent Medical Academy, Tashkent, Uzbekistan

ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a global health concern affecting up to 25% of the world's population. It is characterized by the accumulation of fat in the liver, which can lead to inflammation, fibrosis, and cirrhosis. The exact causes of NAFLD are not fully understood, but there is evidence to suggest that it is closely linked to obesity, insulin resistance, and metabolic syndrome. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in the regulation of gene expression. In recent years, there has been growing interest in the role of miRNAs, particularly miRNA-122, in the pathogenesis of NAFLD. NAFLD is a complex disease that can be divided into two subtypes: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). While NAFL is generally considered to be a benign condition, NASH can progress to advanced liver disease, including cirrhosis and hepatocellular carcinoma. MiRNA-122 is a liver-specific microRNA that plays an important role in the regulation of lipid metabolism and the development of nafld. Studies have shown that mirna-122 is downregulated in the livers of patients with nafld and animal models of the disease. This downregulation is thought to contribute to the development of NAFLD by altering lipid metabolism in the liver. MiRNA-122 regulates the expression of several genes involved in lipid metabolism, including fatty acid synthesis, β-oxidation, and cholesterol metabolism. In animal models of NAFLD, overexpression of miRNA-122 has been shown to reduce hepatic steatosis and inflammation, while inhibition of miRNA-122 exacerbates these features of the disease, suggesting that miRNA-122 plays a protective role in the development of NAFLD.
In conclusion, miRNA-122 appears to play an important role in the pathogenesis of NAFLD, and its dysregulation may contribute to the development and progression of the disease. Further studies are needed to fully elucidate the mechanisms by which miRNA-122 affects lipid metabolism in the liver and to determine its potential as a therapeutic target for the treatment of NAFLD.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a growing health concern worldwide, affecting up to 25% of the global population. NAFLD is characterized by the accumulation of fat in the liver, which can lead to inflammation, fibrosis, and cirrhosis. While the exact

causes of NAFLD are still not fully understood, there is evidence to suggest that it is closely linked to obesity, insulin resistance, and metabolic syndrome. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in the regulation of gene expression. In recent years, there has been growing interest in the role of miRNAs, particularly miRNA-122, in the pathogenesis of NAFLD.

Overview of NAFLD:

NAFLD is a complex disease that can be broadly divided into two subtypes: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NAFL is characterized by the presence of fat in the liver, while NASH is defined by the presence of fat along with inflammation and liver cell damage. While NAFL is generally considered to be a benign condition, NASH can progress to advanced liver disease, including cirrhosis and hepatocellular carcinoma.

Pathogenesis of NAFLD:

Non-alcoholic fatty liver disease (NAFLD) is a complex, multifactorial disease that can progress from simple steatosis (fatty liver) to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC) in some cases. The pathogenesis of NAFLD is not fully understood, but several factors are thought to contribute to its development, including:

1. Insulin resistance: Insulin resistance is a key factor in the development of NAFLD. When cells become resistant to insulin, they are unable to use glucose effectively, leading to increased blood sugar levels. This results in the liver producing more insulin, which can cause the liver to store excess fat.
2. Oxidative stress: Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to detoxify them. ROS can damage cells and tissues, including the liver, leading to inflammation and fibrosis.
3. Lipotoxicity: Lipotoxicity refers to the accumulation of toxic lipids, such as free fatty acids and triglycerides, in liver cells. These lipids can cause damage to the liver, leading to inflammation and fibrosis.
4. Gut microbiota dysbiosis: An imbalance in the gut microbiota, known as dysbiosis, has been linked to the development of NAFLD. Dysbiosis can lead to increased intestinal permeability, allowing bacteria and other toxins to enter the liver and cause inflammation.
5. Genetic factors: Certain genetic mutations have been associated with an increased risk of NAFLD. These mutations can affect the metabolism of fats and sugars, leading to the accumulation of fat in the liver.

Role of miRNA-122 in NAFLD:

miRNA-122 is a liver-specific microRNA that plays an important role in the regulation of lipid metabolism and the development of non-alcoholic fatty liver disease (NAFLD). miRNA-122 is the most abundant microRNA in the liver, accounting for up to 70% of all liver microRNAs.

Studies have shown that miRNA-122 is downregulated in the livers of patients with NAFLD and animal models of the disease. This downregulation is thought to contribute to the development of NAFLD by altering lipid metabolism in the liver. miRNA-122 regulates the expression of several genes involved in lipid metabolism, including fatty acid synthesis, β-oxidation, and cholesterol metabolism.

In animal models of NAFLD, overexpression of miRNA-122 has been shown to reduce hepatic steatosis and inflammation, while inhibition of miRNA-122 exacerbates these features of the disease. This suggests that miRNA-122 plays a protective role in the development of NAFLD.

In addition to its role in lipid metabolism, miRNA-122 has also been shown to regulate hepatic fibrosis, a common complication of NAFLD. In animal models of liver fibrosis, miRNA-122 expression is decreased, and overexpression of miRNA-122 has been shown to reduce liver fibrosis.

Overall, miRNA-122 plays a critical role in the pathogenesis of NAFLD by regulating lipid metabolism and hepatic fibrosis. Further research is needed to fully understand the mechanisms by which miRNA-122 contributes to the development of NAFLD and its potential as a therapeutic target for the disease.

miRNA-122 as a Biomarker for NAFLD:

There is growing interest in the use of miRNA-122 as a biomarker for NAFLD. Studies have shown that miRNA-122 levels are decreased in the serum of NAFLD patients, which suggests that it may be a useful diagnostic biomarker for the disease. Furthermore, miRNA-122 levels have been shown to correlate with disease severity, making it a potential prognostic biomarker as well.

Therapeutic Potential of miRNA-122:

Given the importance of miRNA-122 in the regulation of lipid metabolism and its role in NAFLD, there has been growing interest in the therapeutic potential of miRNA-122 in the treatment of the disease. One approach is to use miRNA-122 mimics to restore miRNA-122 levels in the liver. Studies have shown that this approach can reduce lipid accumulation in the liver and improve liver function in animal models of NAFLD. Another approach is to use miRNA-122 inhibitors to reduce miRNA-122 levels in the liver. While this approach may seem counterintuitive, studies have shown that miRNA-122 inhibitors can also reduce lipid accumulation in the liver and improve liver function in animal models of NAFLD.

Clinical Trials of miRNA-122-Based Therapies:

There are currently several miRNA-122-based therapies in clinical trials for the treatment of NAFLD. One such therapy is Miravirsen, a locked nucleic acid-modified antisense oligonucleotide that targets miRNA-122. A phase 2a clinical trial of Miravirsen in patients with chronic hepatitis C virus infection and elevated liver enzymes showed that the drug was well-tolerated and led to a significant reduction in miRNA-122 levels in the liver. Another miRNA-122-based therapy in clinical development is RG-125 (Qurients), a

GalNAc-conjugated RNAi therapeutic that targets miRNA-122. A phase 1 clinical trial of RG-125 in healthy volunteers showed that the drug was well-tolerated and led to a significant reduction in miRNA-122 levels in the liver.

Conclusion:

NAFLD is a complex and multifactorial disease that is closely linked to obesity, insulin resistance, and metabolic syndrome. While the exact causes of NAFLD are still not fully understood, there is growing evidence to suggest that miRNA-122 plays an important role in the pathogenesis of the disease. miRNA-122 regulates lipid metabolism in the liver and is downregulated in NAFLD patients. Further research is needed to fully understand the role of miRNA-122 in NAFLD and to develop new treatments for the disease.

REFERENCES:

1. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.
2. Friedman, S. L., & Neuschwander-Tetri, B. A. (2018). Non-alcoholic steatohepatitis. In Sleisenger and Fordtran's gastrointestinal and liver disease (pp. 1061-1074). Elsevier.
3. Tilg, H., & Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, 52(5), 1836-1846.
4. Fabbrini, E., Sullivan, S., & Klein, S. (2010). Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 51(2), 679-689.
5. Tilg, H., & Moschen, A. R. (2015). Microbiota and diabetes: an evolving relationship. Gut, 64(9), 1413-1421.
6. Anstee, Q. M., & Day, C. P. (2015). The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Seminars in liver disease, 35(3), 270-290.
7. Tsai, W. C., Hsu, S. D., Hsu, C. S., Lai, T. C., Chen, S. J., Shen, R., ... & Huang, H. D. (2012). MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 49(5), 1571-1582.
8. Li, J., Ghazwani, M., Liu, K., Huang, Y., Chang, L., & Li, Y. (2014). MicroRNA-122 regulates rat hepatic stellate cell activation by targeting the TGF-β signaling pathway. PloS one, 9(6), e95253.
9. Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., & Hoffman, H. M. (2014). NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology, 59(3), 898-910.
10. Bala, S., Marcos, M., Gattu, A., Catalano, D., Szabo, G., & Kodys, K. (2014). Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease. Journal of Biological Chemistry, 289(1), 314-324.
10. Parpibaeva, D. A., Sh, E. N., Musaeva, M. A., Boltaboev, X. K., & Turbanova, U. V. (2023). SIMULATION TRAINING IN MEDICINE: FROM PROBLEM TO SOLUTION.

11. Parpibayeva, D. A., Salimova, N. D., Ergashov, N., Baltabayev, H. Q., & Sultanova, M. X. (2022). Tibbiyotda simulyatsion o'qitish: muammodan yechimgacha.
12. Najmutdinova, D. Q., Parpibaeva, D. A., Salaeva, M. S., Salimova, N. D., Ergashov, N. S., & Sultonova, D. A. (2023). The role of fenofibrate (tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes.
13. Parpibaeva, D. A., Buvamukhamedova, N. T., Ergashev, N. S., Salimova, N. D., & Salaeva, M. S. (2023). Optimization of Functional State of the Liver in Patients with Chd on the Background of Rosuvastatin Intake. *Scholastic: Journal of Natural and Medical Education*, *2*(4), 8-12.
14. Ayupovna, P. D. (2023). EVALUATION OF THE EFFECTIVENESS OF SIMULATION TRAINING IN TEACHING HEART AND LUNG AUSCULTATION.
15. Abdurakhmanov, F. M., Korikhonov, D. N., Yakubov, I. Y., Kasimov, U. K., Atakov, S. S., Okhunov, A. O., & Yarkulov, A. S. (2023). Competency-Based Approach in the Scientific Research Process of Higher Medical Institutions' Teachers.
16. Бувамухамедова, Н., Жаббаров, О., Мирзаева, Г., & Рахматов, А. (2022). Перспективы Применения Ривароксабана В Лечении Пациентов С Хронической Ишемической Болезнью Сердца.
17. Мирзаева, Г. П., Жаббаров, О. О., Аликулов, И. Т., Бувамухамедова, Н. Т., & Рахматов, А. М. (2022). Особенности течения подагрического поражения почек у больных с ожирением.